Dr. Michael Lang is the Global Drug & Device CREA, xTA & Strategy at Boehringer Ingelheim Pharma GmbH & Co. KG, where he leads strategic growth initiatives, drives operational excellence, and champions digital transformation across the organization. With over a decade of experience in innovation and business strategy, he has a proven track record in implementing continuous improvement programs, master data management concepts, and digitalization strategies. Before joining Boehringer Ingelheim in 2021, Dr. Lang held leadership roles in digital business innovation at Schaeffler and product project management at Liebherr Appliances, where he focused on cost optimization, agile development, and digital initiatives.

Boehringer Ingelheim is a family-owned company that has been transforming lives in healthcare since 1885. Its approximately 54,500 employees in 130 markets create value through innovation by infusing long-term, sustainable thinking into our Human Pharma and Animal Health units. The company acknowledges the deep and complex ways the lives of humans and animals are interconnected, works on breakthrough therapies, committed to groundbreaking pharmaceutical innovation across our three business units Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing, co-creating solutions that help millions of people worldwide live longer, healthier lives.